MedPath

Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis

Completed
Conditions
Psoriatic Arthritis
Registration Number
NCT01559038
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Brief Summary

The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
483
Inclusion Criteria
  • Adult >= 18 years old
  • Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel
  • Active Psoriatic Arthritis (PsA) with three (3) or more tender and swollen joints as well as active psoriatic skin lesions or confirmed history of psoriasis
  • Inadequate response or non-tolerant to current disease-modifying antirheumatic drugs (DMARD) based treatment for PsA
Exclusion Criteria
  • Currently participating in another prospective study including controlled clinical trials and observational studies
  • Patient cannot or will not sign informed consent
  • Stable disease with adequate tolerance and response to current treatment and no change in treatment is indicated
  • Previous treatment with anti-tumor necrosis factor (anti-TNF) or other biologic agent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in the Disease Activity Score - 28 (DAS-28)Every 3 months up to 6 months, then every 6 months up to 24 months

The DAS - 28 is calculated using the number of swollen (SJC) and tender (TJC) joints out of 28, the erythrocyte sedimentation rate (ESR) and the patient's global assessment of disease activity using a 100 mm visual analogue scale (VAS)

Secondary Outcome Measures
NameTimeMethod
Duration of Morning Stiffness (min)Every 3 months up to 6 months, then every 6 months up to 24 months

This is ascertained by the treating physician during the patient assessment and is measured in minutes

Dermatology Life Quality Index (DLQI)Baseline, month 6, month12, month 24

This is a self-administered questionnaire comprised of 10 items assessing a patient's skin and problems associated with skin disease. The 10 questions in the DLQI converge into six domains that measure symptoms and feelings, daily activities, leisure, work and / or school, personal relationships and satisfaction with treatment.

Health Assessment Questionnaire - Disability Index (HAQ-DI)Every 3 months up to 6 months, then every 6 months up to 24 months

Self-administered questionnaire measuring the patient's functional ability during the last week.

Patient Global Assessment of Disease Activity (VAS and 5 Point Scale)Every 3 months up to 6 months, then every 6 months up to 24 months

A 100 mm VAS with 0 indicating lowest disease and 100 highest disease activity and a five point Likert Scale (0 - 4) that is completed by the patient at the physician's office

Physician Global Assessment of Disease Activity (VAS and 5 Point Scale)Every 3 months up to 6 months, then every 6 months up to 24 months

This is a 100 mm VAS with 0 indicating lowest disease and 100 highest disease activity a five point Likert Scale (0 - 4) that is completed by the physician during the patient examination

Trial Locations

Locations (41)

Pont, Cranbrook, BC, CA /ID# 69120

🇨🇦

Cranbrook, British Columbia, Canada

Dr. Barbara T. Blumenauer Inc. /ID# 75393

🇨🇦

Kamloops, British Columbia, Canada

Hudson, Kamloops, Canada /ID# 69104

🇨🇦

Kamloops, British Columbia, Canada

Dr. Maqbool R. Sheriff Inc. /ID# 69125

🇨🇦

Nanaimo, British Columbia, Canada

Carmi Medical Clinic /ID# 69128

🇨🇦

Penticton, British Columbia, Canada

Dr. J. Antonio Avina-Zubieta /ID# 71035

🇨🇦

Richmond, British Columbia, Canada

Dr. Alfonso Verdejo Inc. /ID# 69131

🇨🇦

Vancouver, British Columbia, Canada

Dr. Milton F. Baker Inc. /ID# 69085

🇨🇦

Victoria, British Columbia, Canada

Manitoba Clinic /ID# 69113

🇨🇦

Winnipeg, Manitoba, Canada

Nexus Clinical Research /ID# 45622

🇨🇦

St. John's, Newfoundland and Labrador, Canada

Scroll for more (31 remaining)
Pont, Cranbrook, BC, CA /ID# 69120
🇨🇦Cranbrook, British Columbia, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.